Moreover, the addition of CX3CL1 to non-immunogenic doses of MTX-treated dying cancer cells in mouse prophylactic tumour vaccination models resulted in the activation of an adaptive immune response and effectively lengthened survival. This evidence concerns the gene CX3CL1 and neoplasm.